Jiangsu Hansoh Pharmaceutical Co., Ltd.
Registry sponsor category
Industry
- Other names
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Company name
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (147)
- A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects
- A Mass Balance Study of [14C]HS-10504
- A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383
- A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis
- A Phase 3 Study of HS-20094 in Patients With T2DM
- A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone
- A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504
- A Phase I Clinical Trial to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10504
- A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension
- A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors
- A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants
- A Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10506 in Healthy Chinese Adult Participants
- A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers
- A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
- A Phase Ib Study of HS-10504 Combined Therapy in NSCLC
- A Phase II Study of HS-10353 in Participants With Postpartum Depression
- A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients
- A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer